Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses

Table 3 Schedule of procedures

Week	Screening^a	Recruitment^b	Weekly DOT Clinic Visits
Week	≤ 1	1	2	3	N
Potential participants provided with study web-link	X
Provisional informed consent submitted^c	X
Baseline information collected	X^c	X
Written informed consent		X
Inclusion/Exclusion criteria verification		X
Medical history and demographics verification		X
National Health Index documented^c		X
GP Contact details documented		X
Randomisation		X
Review AEs			X	X	X
Confirm no ineligible concurrent medication			X	X	X
DOT administered^d		X^e	X	X	X
Inform GP of study enrolment		X
In case of withdrawn, document cause and inform GP			X	X
Inform GP of study completion					X

^aCommenced once participating site had at least one patient with Nucleic Acid Amplification Test (NAAT)-confirmed SARS-CoV-2 infection
^bCommenced once community attack rate exceeded 0.027% per week
^cNZ only
^dIntervention group only
^eFirst DOT—loading dose of 800 mg of HCQ
DOT Directly observed therapy, N total duration of trial intervention in weeks

ISSN: 1745-6215